GO40558
10 Dec 2020
GO40558
NCT03815058
A study to evaluate the efficacy and safety of RO7198457 in combination with pembrolizumab versus pembrolizumab alone in participants with previously untreated advanced melanoma.
Genentech Inc.
Cancer Type | Melanoma & other skin |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Advanced melanoma |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2019-01-08 |
Anticipated End Date | 2022-09-01 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Dr Rachel Roberts-Thomson |
Recruitment Status | Recruiting |